Abstract:Recent research has indicated that the abnormal expression of the deubiquitinase USP7 induces tumorigenesis via multiple cell pathways, and in particular, the p53-MDM2-USP7 pathway is well understood. USP7 is emerging as a promising target for cancer therapy. However, there are limited reports on USP7 inhibitors. Here we report design, synthesis and biological evaluation of novel quinazolin-4(3H)-one derivatives as potent USP7 inhibitors. Our results indicated that the compounds C9 and C19 exhibited the greatest potency against the USP7 catalytic domain, with IC50 values of 4.86 μM and 1.537 μM, respectively. Ub-AMC assays further confirmed IC50 values of 5.048 μM for C9 and 0.595 μM for C19. MTT assays indicated that gastric cancer MGC-803 cells were more sensitive to these compounds than BGC-823 cells. Flow cytometry analysis revealed that C9 restricted cancer cell growth at the G0/G1 and S phases and inhibited the proliferation and clone formation of MGC-803 cells. Further biochemical experiments indicated that C9 decreased the MDM2 protein level and increased the levels of the tumour suppressors p53 and p21 in a dose-dependent manner. Docking studies predicted that solvent exposure of the side chains of C9 and C19 would uniquely form hydrogen bonds with Met407 of USP7. Additionally, C9 exhibited a remarkable anticancer effect in a zebrafish gastric cancer MGC-803 cell model. Our results demonstrated that quinazolin-4(3H)-one derivatives were suitable as leads for the development of novel USP7 inhibitors and especially for anti-gastric cancer drugs.

Design, Synthesis, and Biological Evaluation of Pyrido[2,3-d]pyrimidin-7(8H)-one Derivatives As Potent USP1 Inhibitors

Design, Synthesis, and Biological Evaluation of Pyrido[2,3- d ]pyrimidin-7(8 H )-one Derivatives As Potent USP1 Inhibitors

Design, Synthesis and Biological Evaluation of 2-Aminopyridine Derivatives As USP7 Inhibitors.

Design, synthesis, biological evaluation and structure-activity relationship study of quinazolin-4(3H)-one derivatives as novel USP7 inhibitors

Design, Synthesis and Biological Evaluation of Novel (Quinolinyl-3-pyridinyl)benzenesulfonamide-based Hydroxamic Acids As PI3K and HDAC Dual Targeting Inhibitors

Design and Synthesis of Benzo-Spirocyclic Derivatives as Potent PARP-1 Inhibitors

Design, Synthesis and Biological Evaluation of (R)-5-methylpyrrolidin-2-ones As P300 Bromodomain Inhibitors with Anti-Tumor Activities in Multiple Tumor Lines.

The discovery of potent USP2/USP8 dual-target inhibitors for the treatment of breast cancer via structure guided optimization of ML364

Design, synthesis, and biological evaluation of quinazolin-4(3H)-one derivatives co-targeting poly(ADP-ribose) polymerase-1 and bromodomain containing protein 4 for breast cancer therapy

Novel 4,5-dihydrospiro[benzo[c]azepine-1,1′-cyclohexan]-3(2H)-one derivatives as PARP-1 inhibitors: Design, synthesis and biological evaluation

Discovery of Quinazoline-2,4(1 H,3 H)-dione Derivatives Containing a Piperizinone Moiety as Potent PARP-1/2 Inhibitors─Design, Synthesis, In Vivo Antitumor Activity, and X-ray Crystal Structure Analysis

Design, Synthesis, Biological Evaluation and Molecular Docking Study of Novel Urea-Based Benzamide Derivatives As Potent Poly(adp-Ribose) Polymerase-1 (PARP-1) Inhibitors

Design, Synthesis, and Bioevaluation of Pyrido[2,3- d]pyrimidin-7-ones as Potent SOS1 Inhibitors

Discovery of pyrazolo[3,4-b]pyridine derivatives as novel and potent Mps1 inhibitors for the treatment of cancer

Design, synthesis, and biological evaluation of a series of benzofuran[3,2-<i>d</i>] pyrimidine-4(3<i>H</i>)-one derivatives containing thiosemicarbazone analogs as novel PARP-1 inhibitors

Design, synthesis, and biological evaluation of novel molecules as potent inhibitors of PLK1

Design, synthesis and biological evaluation of novel phthalazinone acridine derivatives as dual PARP and Topo inhibitors for potential anticancer agents

Design, Synthesis, Antitumor Activity Evaluation, and Molecular Dynamics Simulation of Some 2-Aminopyrazine Derivatives

N-benzylpiperidinol Derivatives As Novel USP7 Inhibitors: Structure-activity Relationships and X-ray Crystallographic Studies

Design, Synthesis and Biological Evaluation of Novel 5-Fluoro-1h-benzimidazole-4-carboxamide Derivatives As Potent PARP-1 Inhibitors.

Structure-based discovery of 1-(3-fluoro-5-(5-(3-(methylsulfonyl)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)phenyl)-3-(pyrimidin-5-yl)urea as a potent and selective nanomolar type-II PLK4 inhibitor